Other
Biovica
Total Trials
2
Recruiting
2
Active
2
Completed
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
Failure Rate
0.0%
0 terminated/withdrawn out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed trials have results
Key Signals
2 recruiting
Enrollment Performance
Analytics
N/A
2(100.0%)
2Total
N/A(2)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (2)
Showing 2 of 2 trials
NCT04968964Not ApplicableRecruiting
Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing
Role: collaborator
NCT05977036Not ApplicableRecruiting
BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer
Role: collaborator
All 2 trials loaded